文献速递骨质疏松与代谢性骨病

阿巴洛肽与特立帕肽在初用促骨形成治疗绝经后女性中的比较有效性与心血管安全性:美国行政理赔数据库研究

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.
PubMed 文献 · Osteoporos Int · 2022-05-07

基于美国行政理赔数据库,纳入初用促骨形成治疗的≥50岁绝经后女性,经1:1倾向评分匹配后每组11616例。随访19个月,阿巴洛肽组与特立帕肽组非椎体骨折风险无显著差异(HR 0.89,95%CI 0.77-1.03),髋部骨折风险降低22%(HR 0.78,95%CI 0.62-1.00),主要不良心血管事件及主要不良心血管事件+心力衰竭发生率相似。

要点

  • 随访19个月,阿巴洛肽组非椎体骨折335例 vs 特立帕肽组375例,HR 0.89(95%CI 0.77-1.03),无显著差异。
  • 阿巴洛肽组髋部骨折121例 vs 特立帕肽组154例,HR 0.78(95%CI 0.62-1.00),风险降低22%。
  • 两组主要不良心血管事件及主要不良心血管事件+心力衰竭发生率相似。

核心结论

  • 治疗18个月后,阿巴洛肽在预防非椎体骨折方面与特立帕肽相当,且两组心血管安全性相似。

研究设计与样本

  • 基于美国Symphony Health Integrated Dataverse(IDV)®数据库2017年5月1日至2019年7月31日的匿名理赔数据,纳入≥50岁、至少1次阿巴洛肽或特立帕肽处方且无既往促骨形成治疗史的绝经后女性,比较阿巴洛肽组与特立帕肽组(NCT04974723)。
  • 采用1:1倾向评分匹配形成两组各11,616例的队列,使用Cox比例风险模型比较索引日期后首次非椎体骨折、主要不良心血管事件(MACE)及MACE+心力衰竭(HF)的发生时间。

主要发现

  • 总体中位年龄(四分位距)为67(61,75)岁,25.6%有骨折史。
  • 随访19个月,阿巴洛肽组335例 vs 特立帕肽组375例发生非椎体骨折,HR 0.89(95%CI 0.77-1.03)。
  • 阿巴洛肽组121例 vs 特立帕肽组154例发生髋部骨折,HR 0.78(95%CI 0.62-1.00),风险降低22%。
  • 两组MACE及MACE+HF发生率相似。

关键数值与推荐

  • 非椎体骨折:阿巴洛肽组335例 vs 特立帕肽组375例,HR 0.89(95%CI 0.77-1.03)。
  • 髋部骨折:阿巴洛肽组121例 vs 特立帕肽组154例,HR 0.78(95%CI 0.62-1.00),风险降低22%。
  • MACE及MACE+HF发生率:两组相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Real-world evidence on the comparative effectiveness and safety of abaloparatide versus teriparatide in women with osteoporosis may help inform treatment decisions. Following 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of nonvertebral fractures, resulted in a 22% risk reduction for hip fractures, and demonstrated similar cardiovascular safety. Osteoporotic fracture risk can be reduced with anabolic or antiresorptive medications. In addition to efficacy and safety data from controlled clinical trials, real-world evidence on comparative effectiveness and safety may help inform treatment decisions. INTRODUCTION: The real-world effectiveness of abaloparatide versus teriparatide on nonvertebral fracture (NVF) incidence and cardiovascular safety during the 19-month period after treatment initiation were evaluated (NCT04974723). METHODS: Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy. Most were enrolled in commercial and Medicare health plans. Index was the date of the initial prescription dispensed during the identification period. In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model. RESULTS: Propensity score matching yielded 11,616 patients per cohort. Overall median age (interquartile range) was 67 (61, 75) years, and 25.6% had a fracture history. Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)]. The MACE and MACE + HF rates were similar between cohorts. CONCLUSIONS: Following 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of NVF and similar cardiovascular safety was demonstrated between cohorts.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cosman F, Cooper C, Wang Y, et al. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporos Int. 2022. PMID: 35524068. doi:10.1007/s00198-022-06413-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。